Degarelix for treating advanced hormone-sensitive prostate cancer

To assess the effects of degarelix compared with standard systemic androgen suppression therapy (in the form of surgical castration, medical castration using GnRH agonists, non-steroidal or steroidal antiandrogen monotherapy, or combination therapy of surgical or medical castration with antiandrogens) for men with advanced hormone-sensitive prostate cancer.

This is a protocol.